{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T01:21:08Z","timestamp":1787966468317,"version":"build-2784847793"},"reference-count":74,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CHR"],"published-print":{"date-parts":[[2020,11,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Long life expectancy in people living with human immunodeficiency virus (PLWH) caused an increase in comorbidities and co-medications. We aimed to analyse co-medications and drug-drug interactions (DDIs) in antiretroviral therapy (ART)-naive PLWH in the era of integrase inhibitors.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> A retrospective observational study was conducted between January 2016-August 2019. Patients\u2019 characteristics\nand chronic co-medications were recorded. The university of Liverpool HIV drug interaction database was used for DDIs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Among 745 patients, the chronic co-medication rate was 30.9%. Older age (p&lt;0.001, OR:6.66, 95% CI: 3.86-\n11.49) and female gender (p=002, OR:2.25, 95%:1.14-4.44) were independently associated with co-medication. Cardiovascular system (CVS) and central nervous system (CNS) drugs were most common co-medications. Older age (p&lt;0.001,\nOR:12.04, 95% CI:4.63-36.71), having heterosexual (HS) contact (p=0.003, OR:3.8, 95% CI:1.57-9.22) were independently\nassociated with CVS drugs use, while being men who have sex with men (MSM) (p=0.03, OR:2.59, 95% CI:1.11-6.03) was\nassociated with CNS drugs use. DDIs were seen in 37.4% of patients with co-medications. Antidiabetics (23.3%), CNS\n(22.1%) and CVS drugs (19.8%) most commonly had DDIs. Contraindication was most commonly seen between inhaled\ncorticosteroids and elvitegravir\/cobicistat. A number of non-ART drugs, elvitegravir\/cobicistat, antidiabetics, vitamins were\nindependently associated with the presence of DDIs.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p> Results suggested the need for attention about co-medication in PLWH regardless of whether they are young or\nolder. CNS drugs should be questioned more detailed in MSM, as well as CVS drugs in older HS patients.\nElvitegravir\/cobicistat is significantly associated with DDIs and switching to an unboosted INSTI should be considered in\npatients with multiple comorbidities.\n<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574885515666200812215140","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T12:11:58Z","timestamp":1597320718000},"page":"415-425","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors"],"prefix":"10.2174","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-1084","authenticated-orcid":true,"given":"Zuhal","family":"Ye\u015filba\u011f","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-2966","authenticated-orcid":true,"given":"Emine \u0130lay","family":"\u015eeng\u00fcl","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4796-9583","authenticated-orcid":true,"given":"Sevtap","family":"\u015eeno\u011flu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-1385","authenticated-orcid":true,"given":"\u00d6zlem Altunta\u015f","family":"Ayd\u0131n","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7716-3006","authenticated-orcid":true,"given":"Hayat Kumbasar","family":"Karaosmano\u011flu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Bakirkoy Dr. Sadi Konuk Education and Research Hospital, Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"Palella F.J.","year":"1998","unstructured":"Palella F.J.; Delaney K.M.; Moorman A.C.; Loveless M.O.; Fuhrer J.; Satten G.A.; Aschman D.J.; Holmberg S.D.; Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med HIV Outpatient Study Investigators1998,338(13),853-860","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/jac\/dkr248","volume":"66","author":"Marzolini C.","year":"2011","unstructured":"Marzolini C.; Back D.; Weber R.; Furrer H.; Cavassini M.; Calmy A.; Vernazza P.; Bernasconi E.; Khoo S.; Battegay M.; Elzi L.; Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother Swiss HIV Cohort Study Members2011,66(9),2107-2111","journal-title":"J Antimicrob Chemother"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3851\/IMP2076","volume":"17","author":"Krentz H.B.","year":"2012","unstructured":"Krentz H.B.; Cosman I.; Lee K.; Ming J.M.; Gill M.J.; Pill burden in HIV infection: 20 years of experience. Antivir Ther (Lond) 2012,17(5),833-840","journal-title":"Antivir Ther (Lond)"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0140-6736(10)60676-9","volume":"376","author":"Volberding P.A.","year":"2010","unstructured":"Volberding P.A.; Deeks S.G.; Antiretroviral therapy and management of HIV infection. Lancet 2010,376(9734),49-62","journal-title":"Lancet"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/jac\/dkv259","volume":"70","author":"Seden K.","year":"2015","unstructured":"Seden K.; Merry C.; Hewson R.; Siccardi M.; Lamorde M.; Byakika-Kibwika P.; Laker E.; Parkes-Ratanshi R.; Back D.J.; Khoo S.H.; Prevalence and type of drug- drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, Uganda. J Antimicrob Chemother 2015,70(12),3317-3322","journal-title":"J Antimicrob Chemother"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1086\/590150","volume":"47","author":"Effros R.B.","year":"2008","unstructured":"Effros R.B.; Fletcher C.V.; Gebo K.; Halter J.B.; Hazzard W.R.; Horne F.M.; Huebner R.E.; Janoff E.N.; Justice A.C.; Kuritzkes D.; Nayfield S.G.; Plaeger S.F.; Schmader K.E.; Ashworth J.R.; Campanelli C.; Clayton C.P.; Rada B.; Woolard N.F.; High K.P.; Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008,47(4),542-553","journal-title":"Clin Infect Dis"},{"key":"ref=7","first-page":"749","volume":"8","author":"Gleason L.J.","year":"2013","unstructured":"Gleason L.J.; Luque A.E.; Shah K.; Polypharmacy in the HIV-infected older adult population. Clin Interv Aging 2013,8,749-763","journal-title":"Clin Interv Aging"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"e0203895","DOI":"10.1371\/journal.pone.0203895","volume":"13","author":"Allavena C.","year":"2018","unstructured":"Allavena C.; Hanf M.; Rey D.; Duvivier C.; BaniSadr F.; Poizot-Martin I.; Jacomet C.; Pugliese P.; Delobel P.; Katlama C.; Joly V.; Chidiac C.; Dournon N.; Merrien D.; May T.; Reynes J.; Gagneux-Brunon A.; Chirouze C.; Huleux T.; Cabi\u00e9 A.; Raffi F.; Antiretroviral exposure and comorbidities in an aging HIV-infected population: The challenge of geriatric patients. PLoS One Dat\u2019AIDS study group2018,13(9),e0203895","journal-title":"PLoS One"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1080\/17512433.2019.1627200","volume":"12","author":"Marzolini C.","year":"2019","unstructured":"Marzolini C.; Livio F.; Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol 2019,12(7),643-659","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/cir627","volume":"53","author":"Guaraldi G.","year":"2011","unstructured":"Guaraldi G.; Orlando G.; Zona S.; Menozzi M.; Carli F.; Garlassi E.; Berti A.; Rossi E.; Roverato A.; Palella F.; Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis 2011,53(11),1120-1126","journal-title":"Clin Infect Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s11904-010-0041-9","volume":"7","author":"Justice A.C.","year":"2010","unstructured":"Justice A.C.; HIV and aging: time for a new paradigm. Curr HIV\/AIDS Rep 2010,7(2),69-76","journal-title":"Curr HIV\/AIDS Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/j.1532-5415.2012.03948.x","volume":"60","year":"2012","unstructured":"Summary report from the Human Immunodeficiency Virus and Aging Consensus Project: treatment strategies for clinicians managing older individuals with the human immunodeficiency virus. J Am Geriatr Soc Work Group for HIV and Aging Consensus Project2012,60(5),974-979","journal-title":"J Am Geriatr Soc"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s40266-013-0093-9","volume":"30","author":"Edelman E.J.","year":"2013","unstructured":"Edelman E.J.; Gordon K.S.; Glover J.; McNicholl I.R.; Fiellin D.A.; Justice A.C.; The next therapeutic challenge in HIV: polypharmacy. Drugs Aging 2013,30(8),613-628","journal-title":"Drugs Aging"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e25449","DOI":"10.1002\/jia2.25449","volume":"23","author":"Back D.","year":"2020","unstructured":"Back D.; Marzolini C.; The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc 2020,23(2),e25449","journal-title":"J Int AIDS Soc"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/jgs.12695","volume":"62","author":"Greene M.","year":"2014","unstructured":"Greene M.; Steinman M.A.; McNicholl I.R.; Valcour V.; Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc 2014,62(3),447-453","journal-title":"J Am Geriatr Soc"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jama.2013.2963","volume":"309","author":"Greene M.","year":"2013","unstructured":"Greene M.; Justice A.C.; Lampiris H.W.; Valcour V.; Management of human immunodeficiency virus infection in advanced age. JAMA 2013,309(13),1397-1405","journal-title":"JAMA"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"e0203890","DOI":"10.1371\/journal.pone.0203890","volume":"13","author":"Ware D.","year":"2018","unstructured":"Ware D.; Palella F.J.; Chew K.W.; Friedman M.R.; D\u2019Souza G.; Ho K.; Plankey M.; Prevalence and trends of polypharmacy among HIV-positive and -negative men in the Multicenter AIDS Cohort Study from 2004 to 2016. PLoS One 2018,13(9),e0203890","journal-title":"PLoS One"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/jac\/dkp152","volume":"64","author":"Seden K.","year":"2009","unstructured":"Seden K.; Back D.; Khoo S.; Antiretroviral drug interactions: often unrecognized, frequently unavoidable, sometimes unmanageable. J Antimicrob Chemother 2009,64(1),5-8","journal-title":"J Antimicrob Chemother"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15284336.2017.1404690","volume":"19","author":"Molas E.","year":"2018","unstructured":"Molas E.; Luque S.; Retamero A.; Echeverr\u00eda-Esnal D.; Guelar A.; Montero M.; Guerri R.; Sorli L.; Lerma E.; Villar J.; Knobel H.; Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team. HIV Clin Trials 2018,19(1),1-7","journal-title":"HIV Clin Trials"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1592\/phco.27.10.1379","volume":"27","author":"Miller C.D.","year":"2007","unstructured":"Miller C.D.; El-Kholi R.; Faragon J.J.; Lodise T.P.; Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 2007,27(10),1379-1386","journal-title":"Pharmacotherapy"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"e16800","DOI":"10.1371\/journal.pone.0016800","volume":"6","author":"Kigen G.","year":"2011","unstructured":"Kigen G.; Kimaiyo S.; Nyandiko W.; Faragher B.; Sang E.; Jakait B.; Owen A.; Back D.; Gibbons S.; Seden K.; Khoo S.H.; Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort. PLoS One USAID-Academic Model for Prevention Treatment of HIV\/AIDS2011,6(2),e16800","journal-title":"PLoS One"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1345\/aph.1P576","volume":"45","author":"Patel N.","year":"2011","unstructured":"Patel N.; Abdelsayed S.; Veve M.; Miller C.D.; Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens. Ann Pharmacother 2011,45(3),317-324","journal-title":"Ann Pharmacother"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11908-011-0229-1","volume":"14","author":"Tseng A.","year":"2012","unstructured":"Tseng A.; Foisy M.; Important drug-drug interactions in HIVinfected persons on antiretroviral therapy: an update on new interactions between HIV and non-HIV drugs. Curr Infect Dis Rep 2012,14(1),67-82","journal-title":"Curr Infect Dis Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1086\/652149","volume":"50","author":"Evans-Jones J.G.","year":"2010","unstructured":"Evans-Jones J.G.; Cottle L.E.; Back D.J.; Gibbons S.; Beeching N.J.; Carey P.B.; Khoo S.H.; Recognition of risk for clinically significant drug interactions among HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2010,50(10),1419-1421","journal-title":"Clin Infect Dis"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/hiv.12205","volume":"16","author":"Iniesta-Naval\u00f3n C.","year":"2015","unstructured":"Iniesta-Naval\u00f3n C.; Franco-Miguel J.J.; Gasc\u00f3n-C\u00e1novas J.J.; Rentero-Redondo L.; Identification of potential clinically significant drug interactions in HIV-infected patients: a comprehensive therapeutic approach. HIV Med 2015,16(5),273-279","journal-title":"HIV Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1365-2710.2003.00541.x","volume":"29","author":"de Maat M.M.","year":"2004","unstructured":"de Maat M.M.; de Boer A.; Koks C.H.; Mulder J.W.; Meenhorst P.L.; van Gorp E.C.; Mairuhu A.T.; Huitema A.D.; Beijnen J.H.; Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther 2004,29(2),121-130","journal-title":"J Clin Pharm Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1177\/0956462412472428","volume":"24","author":"Seden K.","year":"2013","unstructured":"Seden K.; Bradley M.; Miller A.R.; Beadsworth M.B.; Khoo S.H.; The clinical utility of HIV outpatient pharmacist prescreening to reduce medication error and assess adherence. Int J STD AIDS 2013,24(3),237-241","journal-title":"Int J STD AIDS"},{"key":"ref=28","first-page":"109","volume":"98","author":"Katende-Kyenda N.L.","year":"2008","unstructured":"Katende-Kyenda N.L.; Lubbe M.S.; Serfontein J.H.; Truter I.; Prevalence of drug-drug interactions of antiretroviral agents in the private health care sector in South Africa. S Afr Med J 2008,98(2),109-113","journal-title":"S Afr Med J"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1089\/aid.2011.0247","volume":"28","author":"Avihingsanon A.","year":"2012","unstructured":"Avihingsanon A.; van der Lugt J.; Singphore U.; Gorowara M.; Boyd M.; Ananworanich J.; Phanuphak P.; Burger D.; Ruxrungtham K.; Pharmacokinetics and 48 week efficacy of adjusted dose indinavir\/ritonavir in rifampicin-treated HIV\/tuberculosis-coinfected patients: a pilot study. AIDS Res Hum Retroviruses 2012,28(10),1170-1176","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1001\/jama.300.5.530","volume":"300","author":"Boulle A.","year":"2008","unstructured":"Boulle A.; Van Cutsem G.; Cohen K.; Hilderbrand K.; Mathee S.; Abrahams M.; Goemaere E.; Coetzee D.; Maartens G.; Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008,300(5),530-539","journal-title":"JAMA"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1086\/528863","volume":"46","author":"von Wyl V.","year":"2008","unstructured":"von Wyl V.; Yerly S.; B\u00f6ni J.; B\u00fcrgisser P.; Klimkait T.; Battegay M.; Bernasconi E.; Cavassini M.; Furrer H.; Hirschel B.; Vernazza P.L.; Rickenbach M.; Ledergerber B.; G\u00fcnthard H.F.; Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir. Clin Infect Dis Swiss HIV Cohort Study2008,46(8),1299-1309","journal-title":"Clin Infect Dis"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/00002030-200402200-00012","volume":"18","author":"Negredo E.","year":"2004","unstructured":"Negredo E.; Molt\u00f3 J.; Burger D.; Viciana P.; Ribera E.; Paredes R.; Juan M.; Ruiz L.; Puig J.; Pruvost A.; Grassi J.; Masmitj\u00e0 E.; Clotet B.; Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004,18(3),459-463","journal-title":"AIDS"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dks346","volume":"68","author":"Seden K.","year":"2013","unstructured":"Seden K.; Khoo S.H.; Back D.; Byakika-Kibwika P.; Lamorde M.; Ryan M.; Merry C.; Global patient safety and antiretroviral drug-drug interactions in the resource-limited setting. J Antimicrob Chemother 2013,68(1),1-3","journal-title":"J Antimicrob Chemother"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1742-6405-8-18","volume":"8","author":"Okulicz J.F.","year":"2011","unstructured":"Okulicz J.F.; Grandits G.A.; French J.A.; George J.M.; Simpson D.M.; Birbeck G.L.; Ganesan A.; Weintrob A.C.; Crum-Cianflone N.; Lalani T.; Landrum M.L.; Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study. AIDS Res Ther Infectious Disease Clinical Research Program (IDCRP) HIV Working Group2011,8,18","journal-title":"AIDS Res Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1097\/01.qai.0000219769.89679.ec","volume":"41","author":"Bruce R.D.","year":"2006","unstructured":"Bruce R.D.; Altice F.L.; Gourevitch M.N.; Friedland G.H.; Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice. J Acquir Immune Defic Syndr 2006,41(5),563-572","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"e87338","DOI":"10.1371\/journal.pone.0087338","volume":"9","author":"Agu K.A.","year":"2014","unstructured":"Agu K.A.; Oqua D.; Adeyanju Z.; Isah M.A.; Adesina A.; Ohiaeri S.I.; Ali P.N.; Ekechukwu N.; Akpakwu A.A.; Sani T.; Omeh I.O.; King R.C.; Wutoh A.K.; The incidence and types of medication errors in patients receiving antiretroviral therapy in resource-constrained settings. PLoS One 2014,9(1),e87338","journal-title":"PLoS One"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/1060028016685115","volume":"51","author":"Jakeman B.","year":"2017","unstructured":"Jakeman B.; Nasiri M.; Ruth L.; Morse C.; Mahatme S.; Patel N.; Comparing the frequencies of contraindicated drug-drug interactions between differing antiretroviral regimens in HIV-infected patients. Ann Pharmacother 2017,51(5),365-372","journal-title":"Ann Pharmacother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.2146\/ajhp170613","volume":"75","author":"Patel N.","year":"2018","unstructured":"Patel N.; Borg P.; Haubrich R.; McNicholl I.; Analysis of drug-drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. Am J Health Syst Pharm 2018,75(15),1132-1139","journal-title":"Am J Health Syst Pharm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1517\/17425255.2014.993606","volume":"11","author":"Farhoudi M.","year":"2015","unstructured":"Farhoudi M.; Khalili H.; Karimzadeh I.; Abbasian L.; Associated factors of drug-drug interactions of highly active antiretroviral therapy: report from a referral center. Expert Opin Drug Metab Toxicol 2015,11(4),471-479","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1592\/phco.31.5.480","volume":"31","author":"Yiu P.","year":"2011","unstructured":"Yiu P.; Nguyen N.N.; Holodniy M.; Clinically significant drug interactions in younger and older human immunodeficiency virus-positive patients receiving antiretroviral therapy. Pharmacotherapy 2011,31(5),480-489","journal-title":"Pharmacotherapy"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1001\/jama.2018.8431","volume":"320","author":"Saag M.S.","year":"2018","unstructured":"Saag M.S.; Benson C.A.; Gandhi R.T.; Hoy J.F.; Landovitz R.J.; Mugavero M.J.; Sax P.E.; Smith D.M.; Thompson M.A.; Buchbinder S.P.; Del Rio C.; Eron J.J.; F\u00e4tkenheuer G.; G\u00fcnthard H.F.; Molina J.M.; Jacobsen D.M.; Volberding P.A.; Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA 2018,320(4),379-396","journal-title":"JAMA"},{"key":"ref=42","year":"2019","unstructured":"EACS guidelines version 100 2019","journal-title":"EACS guidelines version 100"},{"key":"ref=43","unstructured":"Liverpool HIV drug interactions","journal-title":"Liverpool HIV drug interactions"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/S1473-3099(15)00056-0","volume":"15","author":"Smit M.","year":"2015","unstructured":"Smit M.; Brinkman K.; Geerlings S.; Smit C.; Thyagarajan K.; Sighem Av.; de Wolf F.; Hallett T.B.; Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis ATHENA observational cohort2015,15(7),810-818","journal-title":"Lancet Infect Dis"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/cid\/cir626","volume":"53","author":"Hasse B.","year":"2011","unstructured":"Hasse B.; Ledergerber B.; Furrer H.; Battegay M.; Hirschel B.; Cavassini M.; Bertisch B.; Bernasconi E.; Weber R.; Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis Swiss HIV Cohort Study2011,53(11),1130-1139","journal-title":"Clin Infect Dis"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1086\/523577","volume":"45","author":"Goulet J.L.","year":"2007","unstructured":"Goulet J.L.; Fultz S.L.; Rimland D.; Butt A.; Gibert C.; Rodriguez-Barradas M.; Bryant K.; Justice A.C.; Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis 2007,45(12),1593-1601","journal-title":"Clin Infect Dis"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2174\/157016209789973691","volume":"7","author":"Mothe B.","year":"2009","unstructured":"Mothe B.; Perez I.; Domingo P.; Podzamczer D.; Ribera E.; Curran A.; Vilad\u00e9s C.; Vidal F.; Dalmau D.; Pedrol E.; Negredo E.; Molt\u00f3 J.; Paredes R.; Perez-Alvarez N.; Gatell J.M.; Clotet B.; HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain. Curr HIV Res 2009,7(6),597-600","journal-title":"Curr HIV Res"},{"key":"ref=48","first-page":"618","volume":"41","author":"Bastida C.","year":"2017","unstructured":"Bastida C.; Grau A.; M\u00e1rquez M.; Tuset M.; De Lazzari E.; Mart\u00ednez E.; Gatell J.M.; Polypharmacy and potential drug-drug interactions in an HIV-infected elderly population. Farm Hosp 2017,41(5),618-624","journal-title":"Farm Hosp"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1179\/1528433614Z.0000000012","volume":"16","author":"Gimeno-Gracia M.","year":"2015","unstructured":"Gimeno-Gracia M.; Crusells-Canales M.J.; Javier Armesto-G\u00f3mez F.; Rabanaque-Hern\u00e1ndez M.J.; Prevalence of concomitant medications in older HIV+ patients and comparison with general population. HIV Clin Trials 2015,16(3),117-124","journal-title":"HIV Clin Trials"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3851\/IMP1540","volume":"15","author":"Marzolini C.","year":"2010","unstructured":"Marzolini C.; Elzi L.; Gibbons S.; Weber R.; Fux C.; Furrer H.; Chave J.P.; Cavassini M.; Bernasconi E.; Calmy A.; Vernazza P.; Khoo S.; Ledergerber B.; Back D.; Battegay M.; Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther (Lond) Swiss HIV Cohort Study2010,15(3),413-423","journal-title":"Antivir Ther (Lond)"},{"key":"ref=51","first-page":"235","volume":"75","author":"Baecke C.","year":"2017","unstructured":"Baecke C.; Gyssens I.C.; Decoutere L.; van der Hilst J.C.H.; Messiaen P.; Prevalence of drug-drug interactions in the era of HIV integrase inhibitors: a retrospective clinical study. Neth J Med 2017,75(6),235-240","journal-title":"Neth J Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e019985","DOI":"10.1136\/bmjopen-2017-019985","volume":"8","author":"Ruzicka D.J.","year":"2018","unstructured":"Ruzicka D.J.; Imai K.; Takahashi K.; Naito T.; Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: a cross-sectional study using a hospital claims database. BMJ Open 2018,8(6),e019985","journal-title":"BMJ Open"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4067\/S0716-10182016000700006","volume":"33","author":"C\u00f3rdova E.","year":"2016","unstructured":"C\u00f3rdova E.; Porteiro N.; Loiza E.; Mingrone H.; [Prevalence of potential drug-drug interactions involving antiretroviral drugs in Buenos Aires, Argentina]. Rev Chilena Infectol 2016,33(Suppl. 1),54-59","journal-title":"Rev Chilena Infectol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/hiv.12801","volume":"21","author":"Schlaeppi C.","year":"2020","unstructured":"Schlaeppi C.; Vanobberghen F.; Sikalengo G.; Glass T.R.; Ndege R.C.; Foe G.; Kuemmerle A.; Paris D.H.; Battegay M.; Marzolini C.; Weisser M.; Prevalence and management of drug-drug interactions with antiretroviral treatment in 2069 people living with HIV in rural Tanzania: a prospective cohort study. HIV Med Kilombero and Ulanga Antiretroviral Cohort (KIULARCO) study group2020,21(1),53-63","journal-title":"HIV Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3906\/sag-1807-295","volume":"49","author":"Kara E.","year":"2019","unstructured":"Kara E.; \u0130nkaya A.\u00c7.; Ayd\u0131n Hakl\u0131 D.; Demirkan K.; \u00dcnal S.; Polypharmacy and drug-related problems among people living with HIV\/AIDS: a single-center experience. Turk J Med Sci 2019,49(1),222-229","journal-title":"Turk J Med Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s11908-009-0036-0","volume":"11","author":"Gebo K.A.","year":"2009","unstructured":"Gebo K.A.; Justice A.; HIV infection in the elderly. Curr Infect Dis Rep 2009,11(3),246-254","journal-title":"Curr Infect Dis Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1310\/hct1102-100","volume":"11","author":"Onen N.F.","year":"2010","unstructured":"Onen N.F.; Overton E.T.; Seyfried W.; Stumm E.R.; Snell M.; Mondy K.; Tebas P.; Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 2010,11(2),100-109","journal-title":"HIV Clin Trials"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"e002378","DOI":"10.1136\/bmjopen-2012-002378","volume":"3","author":"Loikas D.","year":"2013","unstructured":"Loikas D.; Wettermark B.; von Euler M.; Bergman U.; Schenck- Gustafsson K.; Differences in drug utilisation between men and women: a cross-sectional analysis of all dispensed drugs in Sweden. BMJ Open 2013,3(5),e002378","journal-title":"BMJ Open"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/jwh.2012.3972","volume":"23","author":"Manteuffel M.","year":"2014","unstructured":"Manteuffel M.; Williams S.; Chen W.; Verbrugge R.R.; Pittman D.G.; Steinkellner A.; Influence of patient sex and gender on medication use, adherence, and prescribing alignment with guidelines. J Womens Health (Larchmt) 2014,23(2),112-119","journal-title":"J Womens Health (Larchmt)"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cpr.2005.02.001","volume":"25","author":"Meade C.S.","year":"2005","unstructured":"Meade C.S.; Sikkema K.J.; HIV risk behavior among adults with severe mental illness: a systematic review. Clin Psychol Rev 2005,25(4),433-457","journal-title":"Clin Psychol Rev"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1097\/00002030-200401001-00008","volume":"18","author":"Justice A.C.","year":"2004","unstructured":"Justice A.C.; McGinnis K.A.; Atkinson J.H.; Heaton R.K.; Young C.; Sadek J.; Madenwald T.; Becker J.T.; Conigliaro J.; Brown S.T.; Rimland D.; Crystal S.; Simberkoff M.; Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: Veterans Aging Cohort Five-Site Study. AIDS Veterans Aging Cohort 5-Site Study Project Team2004,18(Suppl. 1),S49-S59","journal-title":"AIDS"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/13548506.2011.554645","volume":"16","author":"Sivasubramanian M.","year":"2011","unstructured":"Sivasubramanian M.; Mimiaga M.J.; Mayer K.H.; Anand V.R.; Johnson C.V.; Prabhugate P.; Safren S.A.; Suicidality, clinical depression, and anxiety disorders are highly prevalent in men who have sex with men in Mumbai, India: findings from a community-recruited sample. Psychol Health Med 2011,16(4),450-462","journal-title":"Psychol Health Med"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3390\/ijerph16152667","volume":"16","author":"Jiang T.","year":"2019","unstructured":"Jiang T.; Zhou X.; Wang H.; Luo M.; Pan X.; Ma Q.; Chen L.; Psychosocial factors associated with quality of life in young men who have sex with men living with HIV\/AIDS in Zhejiang, China. Int J Environ Res Public Health 2019,16(15),2667","journal-title":"Int J Environ Res Public Health"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1007\/s11606-013-2449-6","volume":"28","author":"Holtzman C.","year":"2013","unstructured":"Holtzman C.; Armon C.; Tedaldi E.; Chmiel J.S.; Buchacz K.; Wood K.; Brooks J.T.; Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med  and the HOPS Investigators2013,28(10),1302-1310","journal-title":"J Gen Intern Med"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/QAD.0000000000001685","volume":"32","author":"Siefried K.J.","year":"2018","unstructured":"Siefried K.J.; Mao L.; Cysique L.A.; Rule J.; Giles M.L.; Smith D.E.; McMahon J.; Read T.R.; Ooi C.; Tee B.K.; Bloch M.; de Wit J.; Carr A.; Concomitant medication polypharmacy, interactions and imperfect adherence are common in Australian adults on suppressive antiretroviral therapy. AIDS PAART study investigators2018,32(1),35-48","journal-title":"AIDS"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1177\/1060028013504075","volume":"47","author":"Tseng A.","year":"2013","unstructured":"Tseng A.; Szadkowski L.; Walmsley S.; Salit I.; Raboud J.; Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother 2013,47(11),1429-1439","journal-title":"Ann Pharmacother"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/QAI.0000000000001653","volume":"78","author":"Ranzani A.","year":"2018","unstructured":"Ranzani A.; Oreni L.; Agr\u00f2 M.; van den Bogaart L.; Milazzo L.; Giacomelli A.; Cattaneo D.; Gervasoni C.; Ridolfo A.L.; Burden of exposure to potential interactions between antiretroviral and non-antiretroviral medications in a population of HIV-positive patients aged 50 years or older. J Acquir Immune Defic Syndr 2018,78(2),193-201","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jiac.2020.04.003","volume":"26","author":"Chen R.","year":"2020","unstructured":"Chen R.; Chen J.; Tang Q.; Meng Z.; Luo L.; Zhang W.; Deng A.; Zhang L.; Wang J.; Qi T.; Zhang R.; Shen Y.; Liu L.; Steinhart C.; Lu H.; Use of comedications and potential drug-drug interactions in people living with HIV in China. J Infect Chemother 2020,26(7),722-728","journal-title":"J Infect Chemother"},{"key":"ref=69","first-page":"163","volume":"42","author":"N\u00fa\u00f1ez-N\u00fa\u00f1ez M.","year":"2018","unstructured":"N\u00fa\u00f1ez-N\u00fa\u00f1ez M.; Casta\u00f1eda-Mac\u00edas I.; Sandoval-Fern\u00e1ndez Del Castillo S.; Potential interactions in a cohort of elderly hiv-positive patients. Farm Hosp 2018,42(4),163-167","journal-title":"Farm Hosp"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"ofz051","DOI":"10.1093\/ofid\/ofz051","volume":"6","author":"Demessine L.","year":"2019","unstructured":"Demessine L.; Peyro-Saint-Paul L.; Gardner E.M.; Ghosn J.; Parienti J.J.; Risk and cost associated with drug-drug interactions among aging HIV patients receiving combined antiretroviral therapy in France. Open Forum Infect Dis 2019,6(3),ofz051","journal-title":"Open Forum Infect Dis"},{"key":"ref=71","first-page":"ciz811","author":"L\u00f3pez-Centeno B.","year":"2019","unstructured":"L\u00f3pez-Centeno B.; Badenes-Olmedo C.; Mataix-Sanjuan \u00c1.; Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid, Spain: a population-based study. Clin Infect Dis 2019,ciz811","journal-title":"Clin Infect Dis"},{"key":"ref=72","year":"2018","unstructured":"Updated recommendations on f\u0131rst-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV World Health Organization (WHO)2018","journal-title":"Updated recommendations on f\u0131rst-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV"},{"key":"ref=73","year":"2015","unstructured":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015","journal-title":"British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy"},{"key":"ref=74","year":"2019","unstructured":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV 2019","journal-title":"Guidelines for the use of antiretroviral agents in adults and adolescents with HIV"}],"container-title":["Current HIV Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/184810","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184810\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/184810","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,22]],"date-time":"2021-07-22T14:05:25Z","timestamp":1626962725000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184810\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,9]]},"references-count":74,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574885515666200812215140","relation":{},"ISSN":["1570-162X"],"issn-type":[{"value":"1570-162X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}